Characterization of the Expression and Activity of Carboxylesterases 1 and 2 from the Beagle Dog, Cynomolgus Monkey, and Human

被引:60
作者
Williams, Eric T. [1 ]
Bacon, James A. [1 ]
Bender, David M. [3 ]
Lowinger, Jennifer J. [1 ]
Guo, Wen-Kai [1 ]
Ehsani, Mariam E. [2 ]
Wang, Xiliang [2 ]
Wang, He [2 ]
Qian, Yue-Wei [2 ]
Ruterbories, Kenneth J. [1 ]
Wrighton, Steven A. [1 ]
Perkins, Everett J. [1 ]
机构
[1] Eli Lilly & Co, Lilly Res Labs, Dept Drug Disposit, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Lilly Res Labs, Dept Integrat Biol, Indianapolis, IN 46285 USA
[3] Eli Lilly & Co, Lilly Res Labs, Dept Chem, Indianapolis, IN 46285 USA
关键词
HUMAN LIVER CARBOXYLESTERASE; SUBSTRATE-SPECIFICITY; SMALL-INTESTINE; HYDROLYSIS; ESTERASES; TARGETS; CLONING; COCAINE;
D O I
10.1124/dmd.111.041335
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The carboxylesterases (CESs) are a family of serine hydrolases that hydrolyze compounds containing an ester, amide, or thioester. In humans, two dominant forms, CES1 and CES2, are highly expressed in organs of first-pass metabolism and play an important role in xenobiotic metabolism. The current study was conducted to better understand species-related differences in substrate selectivity and tissue expression of these enzymes. To elucidate potential similarities and differences among these enzymes, a series of 4-nitrophenyl esters and a series of gemcitabine prodrugs were evaluated using enzyme kinetics as substrates of expressed and purified CESs from beagle dog, cynomolgus monkey, and human genes. For the substrates examined, human and monkey CES2 more efficiently catalyzed hydrolysis compared with CES1, whereas CES1 was the more efficient enzyme in dog. Quantitative real-time polymerase chain reaction and Western blot analyses indicate that the pattern of CES tissue expression in monkey is similar to that of human, but the CES expression in dog is unique, with no detectable expression of CES in the intestine. Loperamide, a selective human CES2 inhibitor, was also found to be a CES2-selective inhibitor in both dog and monkey. This is the first study to examine substrate specificity among dog, human, and monkey CESs.
引用
收藏
页码:2305 / 2313
页数:9
相关论文
共 17 条
[1]  
Berry Loren M, 2009, Drug Metab Lett, V3, P70
[2]   HUMAN LIVER COCAINE ESTERASES - ETHANOL-MEDIATED FORMATION OF ETHYLCOCAINE [J].
DEAN, RA ;
CHRISTIAN, CD ;
SAMPLE, RHB ;
BOSRON, WF .
FASEB JOURNAL, 1991, 5 (12) :2735-2739
[3]  
Humerickhouse R, 2000, CANCER RES, V60, P1189
[4]   Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine [J].
Imai, Teruko ;
Taketani, Megumi ;
Shii, Mayumi ;
Hosokawa, Masakiyo ;
Chiba, Kan .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (10) :1734-1741
[5]   Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma [J].
Li, B ;
Sedlacek, M ;
Manoharan, I ;
Boopathy, R ;
Duysen, EG ;
Masson, P ;
Lockridge, O .
BIOCHEMICAL PHARMACOLOGY, 2005, 70 (11) :1673-1684
[6]   cDNA cloning, characterization and stable expression of novel human brain carboxylesterase [J].
Mori, M ;
Hosokawa, M ;
Ogasawara, Y ;
Tsukada, E ;
Chiba, K .
FEBS LETTERS, 1999, 458 (01) :17-22
[7]   Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin [J].
Pindel, EV ;
Kedishvili, NY ;
Abraham, TL ;
Brzezinski, MR ;
Zhang, J ;
Dean, RA ;
Bosron, WF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (23) :14769-14775
[8]   Carboxylesterases - Ddetoxifying enzymes and targets for drug therapy [J].
Potter, PM ;
Wadkins, RM .
CURRENT MEDICINAL CHEMISTRY, 2006, 13 (09) :1045-1054
[9]   Hydrolysis of capecitabine to 5′-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide [J].
Quinney, SK ;
Sanghani, SP ;
Davis, WI ;
Hurley, TD ;
Sun, Z ;
Murry, DJ ;
Bosron, WF .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) :1011-1016
[10]   Mammalian carboxylesterases: from drug targets to protein therapeutics [J].
Redinbo, MR ;
Potter, PM .
DRUG DISCOVERY TODAY, 2005, 10 (05) :313-+